Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment


On December 1, 2017, Dr. Il-Kang Na will be assuming the position of BIH Johanna Quandt Professor for Therapy-Induced Remodeling in Immuno-Oncology at Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin.

As malignant tumors develop differently in every person, no two cancers are ever the same. Scientists are constantly gaining a better understanding of why this is the case, allowing them to create far more precise and personalized therapies for every patient. But how exactly does the chosen treatment method affect the tumor, the immune system, and the relationship between the two? And how can these therapies be further adapted and improved?

Il-Kang Na, Axel R. Pries, Dean Charité – Universitätsmedizin Berlin

Il-Kang Na’s research is dedicated to finding answers to these questions. So far, her work has led her to discover certain immunodeficiencies caused by cancer therapies and to develop innovative ideas for new therapy approaches. Na discovered, for example, that cancer therapies can significantly impact the formation, function, and survival of the body’s own immune cells. She also successfully developed a model that allows her to observe how certain immune cells react during cell therapy.

Na has a clear goal in her position as BIH Johanna Quandt Professor: She wants to establish a monitoring system that provides detailed information about important disease and immune system parameters during treatment. “A patient’s course of therapy is initially determined on the basis of specific tumor and patient characteristics,” says Na.

“The chosen therapy is usually only changed if and when clinical or imaging data show that the tumor is growing and spreading despite treatment.” But, she explains, a lot of time can pass before this comes about: “We therefore need to pay far more attention to changes in the tumor, its environment, and the immune system during treatment. This is the only way that we can recognize early on if a patient is not responding to treatment.” These changes are dynamic and hinder the efficacy of both medication and the body’s own immune defenses.

With the help of modern bioanalytical high-throughput technologies, the professor wants to develop a comprehensive tool that can record and monitor molecular and genetic changes at various moments during therapy. This tool would allow cancer treatment to be tailored to the individual patient and thus be significantly improved. Na wants to begin by developing a monitoring system for patients with diffuse large B-cell lymphoma – a cancer that originates from an immune cell. “My long-term goal is to also apply this technique to other treatments and diseases – not just cancer.”

“We are living in an age where new targeted cancer therapies and immunotherapies are progressing at a very fast pace,” says Professor Martin Lohse, spokesperson of the BIH Executive Board and Scientific Directorate, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC). “With her work, Professor Na is ensuring that these therapies can continue to be even more accurately tailored to the personal disease progression of every cancer patient.”

Il-Kang Na
Il-Kang Na, born in Berlin in 1977, studied medicine at Freie Universität Berlin. She received her doctorate there in 2004, and then joined Charité for her residency and as a postdoc. After a postdoc fellowship at Memorial Sloan Kettering Cancer Center in New York City, Na started her own research group, Applied Transplantation Immunology, at the MDC’s and Charité’s Experimental and Clinical Research Center (ECRC) in Berlin, where she also completed her postdoctoral lecture qualification in 2011. Na has received numerous awards for her research, including fellowships and research grants from the German Cancer Aid, the Else Kröner-Fresenius-Stiftung, and the German Research Foundation as well as the BSIO Female Independency Award.

BIH Johanna Quandt Professorships
Il-Kang Na is the third physician, after Petra Ritter and Ute Scholl, to be appointed to one of three newly created BIH Johanna Quandt Professorships that support the advancement of translational research. With the BIH Johanna Quandt Professorships, the Stiftung Charité supports the establishment of three W2 professorships at BIH specifically for women. Each of the professorships is coupled with a long-term perspective from the very beginning and therefore represents a pilot scheme for introducing a real tenure track. Another special feature of the BIH Johanna Quandt Professorships is that the applicants themselves determine the research focus of their professorship. The decisive factor for the selection was the innovative and interdisciplinary orientation with a translational approach. With the BIH Johanna Quandt Professorships, BIH, Charité, and Stiftung Charité are helping to ensure equal opportunities within the Berlin health-research sector.

Alexandra Hensel | idw - Informationsdienst Wissenschaft
Further information:

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

Latest News

Nonstop Tranport of Cargo in Nanomachines

20.11.2018 | Life Sciences

Researchers find social cultures in chimpanzees

20.11.2018 | Life Sciences

When AI and optoelectronics meet: Researchers take control of light properties

20.11.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>